Retina (Philadelphia, Pa.) · 2026
INCIDENCE AND ENLARGEMENT RATE OF MYOPIC MACULAR NEOVASCULARIZATION-RELATED ATROPHY IN HIGHLY MYOPIC EYES.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moukadem Omar, Motloch Karolina, Couanon Marie, Gaucher David, Philippakis Elise, Couturier Aude
Аннотация
PURPOSE: To investigate the incidence and enlargement rate of myopic macular neovascularization (MNV)-related atrophy in highly myopic eyes.
METHODS: This retrospective observational study included highly myopic eyes treated for myopic MNV followed for ≥24 months. Atrophy was defined as a retinal pigment epithelium disruption with hypertransmission on spectral-domain optical coherence tomography. The atrophic area detected on spectral-domain optical coherence tomography was delineated manually on en-face infrared images and measured with a built-in feature. Only eyes with tessellated fundus or diffuse atrophy at baseline were included. Eyes with preexisting retinal pigment epithelium atrophy, including patchy/MNV-related atrophy, were excluded.
RESULTS: Among 473 MNV eyes, 44 eyes of 40 patients (mean follow-up: 75.4 ± 37.7 months) met the inclusion criteria. Fifteen eyes (34.1%) developed MNV-related atrophy 23.37 ± 18.02 months after MNV onset. The atrophy area increased from 0.38 ± 0.67 mm 2 at diagnosis to 1.08 ± 1.45 mm 2 after 45.77 ± 26.45 months ( P = 0.011), corresponding to an enlargement rate of 0.22 ± 0.25 mm 2 /year. Larger MNV diameter and male gender were associated with MNV-related atrophy development.
CONCLUSION: In highly myopic eyes without preexisting retinal pigment epithelium atrophy, one third showed MNV-related atrophy within 2 years of MNV onset. The atrophy enlargement rate was 0.22 ± 0.25 mm 2 /year, highlighting the importance of close monitoring.
METHODS: This retrospective observational study included highly myopic eyes treated for myopic MNV followed for ≥24 months. Atrophy was defined as a retinal pigment epithelium disruption with hypertransmission on spectral-domain optical coherence tomography. The atrophic area detected on spectral-domain optical coherence tomography was delineated manually on en-face infrared images and measured with a built-in feature. Only eyes with tessellated fundus or diffuse atrophy at baseline were included. Eyes with preexisting retinal pigment epithelium atrophy, including patchy/MNV-related atrophy, were excluded.
RESULTS: Among 473 MNV eyes, 44 eyes of 40 patients (mean follow-up: 75.4 ± 37.7 months) met the inclusion criteria. Fifteen eyes (34.1%) developed MNV-related atrophy 23.37 ± 18.02 months after MNV onset. The atrophy area increased from 0.38 ± 0.67 mm 2 at diagnosis to 1.08 ± 1.45 mm 2 after 45.77 ± 26.45 months ( P = 0.011), corresponding to an enlargement rate of 0.22 ± 0.25 mm 2 /year. Larger MNV diameter and male gender were associated with MNV-related atrophy development.
CONCLUSION: In highly myopic eyes without preexisting retinal pigment epithelium atrophy, one third showed MNV-related atrophy within 2 years of MNV onset. The atrophy enlargement rate was 0.22 ± 0.25 mm 2 /year, highlighting the importance of close monitoring.